InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations

InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations

Abstract Background Fibrinogen is the first qualified prognostic/predictive biomarker for exacerbations in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial investigated fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI and UMEC/VI in pat...

Full description

Bibliographic Details
Main Authors: Dave Singh, Gerard J. Criner, Mark T. Dransfield, David M. G. Halpin, MeiLan K. Han, Peter Lange, Sally Lettis, David A. Lipson, David Mannino, Neil Martin, Fernando J. Martinez, Bruce E. Miller, Robert Wise, Chang-Qing Zhu, David Lomas
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Respiratory Research
Subjects:
Fibrinogen
COPD exacerbations
Pharmacotherapy
COPD
Online Access:https://doi.org/10.1186/s12931-021-01706-y

Internet

https://doi.org/10.1186/s12931-021-01706-y

Similar Items